Latest News

Roche expands its US presence by $700 Million in North Carolina

Roche Group announced on Monday it will invest over $700 million into a new manufacturing facility in North Carolina. The company is the latest to expand their presence in the United States in response to President Donald Trump’s tariff policies.

The new facility in Holly Springs, North Carolina will support Roche's and Genentech’s future portfolio of obesity drugs.

In March, Roche acquired the rights to petrelintide from Zealand Pharma of Denmark. This therapy is currently in mid-stage clinical trial.

Roche's obesity pipeline includes drugs that treat obesity and diabetes from Carmot Therapeutics, which it acquired in 2023.

The company stated that "this initial investment may expand in the future based on the business needs and U.S. policies."

Roche announced in April that it will invest $50 billion over the next five-years in the United States, and plans to create 12,000 new jobs.

This announcement is part a broader trend in which drugmakers like Eli Lilly and Johnson & Johnson have made massive investments. Gilead has also pledged to increase its domestic production as a response to President Trump’s tariff policies.

The Trump administration is pressuring U.S. pharmaceutical companies to move production in-house. Last week, the President signed an executive directive to speed up approvals for pharmaceutical plants, encouraging U.S. manufacturing.

Trump has also stated that he

Plans to Sign

He said that the executive order aimed to align US drug prices with those of other countries. This move, he claimed on social media, could lead to a 59% drop in drug costs. (Reporting and editing by Tasim Zaid and Shailesh Kuber in Bengaluru)

(source: Reuters)